EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial

Michael Klotsman, Wayne H Anderson, Danielle Wyatt, Tom Lewis, Natalie Theus, Domenico Santoro iD

Veterinary Dermatology · 2024

DOI: 10.1111/vde.13283 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Veterinary Dermatology, 2024. Verfasst von Michael Klotsman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Okava Pharmaceuticals, San Francisco, California, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Mycophenolic Acid, Drug Liberation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Okava Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycophenolate is an immunomodulating agent successfully used for the treatment of moderate‐to‐severe atopic dermatitis (AD) in people. Mycophenolate is an effective steroid‐sparing treatment option for use in dogs with inflammatory skin diseases.

Objective

To evaluate whether once‐daily modified‐release mycophenolate (OKV‐1001) is safe and effective for treating moderate‐to‐severe canine AD. Animals Client‐owned atopic dogs ( n = 9) were enrolled. Materials and Methods In an open‐label multicentre pilot study, OKV‐1001 (30 mg/kg every 24 h) was given orally for ≤84 days. Concomitant tapering doses of glucocorticoids were administered up to Day (D)28. Clinicians assessed Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04) on D0, D14, D28, D56 and D84. Body weight and clinical pathological parameters were measured at baseline and at the end of the study.

Results

Treatment with OKV‐1001 combined with glucocorticoids significantly reduced the severity of AD within two weeks in seven of nine (77.8%) dogs. The mean percentage change from baseline in the CADESI‐04 score was 29% ( p = 0.009) at D14 ( n = 9), 39% ( p = 0.008) at D28 ( n = 9) and 49% ( p = 0.03) at D56 ( n = 7) at which point glucocorticoids had been withdrawn. In two dogs the improvement in CADESI‐04 was 62% and 23% (respectively) on D84. No significant adverse events including clinical pathological findings were reported. Conclusions and Clinical Relevance Modified‐release mycophenolate (OKV‐1001) may represent a promising alternative treatment option for dogs with moderate‐to‐severe AD. The safety and efficacy profile of OKV‐1001 will need to be established in larger, placebo‐controlled clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicDog DiseasesMycophenolic AcidDrug LiberationAnimalsDogsFemaleMaleDelayed-Action PreparationsDrug Therapy, CombinationGlucocorticoidsImmunosuppressive AgentsPilot ProjectsSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

canine atopic dermatitismoderate‐to‐severemodified‐releasemycophenolatemycophenolic acid

Substanzen

Delayed-Action PreparationsGlucocorticoidsImmunosuppressive AgentsMycophenolic Acid

Autor:innen und Institutionen

  • Okava Pharmaceuticals, San Francisco, California, USA.
  • Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Dermatology Clinic for Animals, Lacey, Washington, USA.
  • Dermatology for Animals, Gilbert, Arizona, USA.
  • MedVet Columbus, Worthington, Ohio, USA.
  • Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Domenico Santoro

Förderung

  • Okava Pharmaceuticals

Zitieren

APA

Klotsman, M., Anderson, W. H., Wyatt, D., Lewis, T., Theus, N., & Santoro, D. (2024). Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial. Veterinary Dermatology. https://doi.org/10.1111/vde.13283

Vancouver

Klotsman M, Anderson WH, Wyatt D, Lewis T, Theus N, Santoro D. Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial. Veterinary Dermatology. 2024. doi:10.1111/vde.13283

BibTeX
@article{Klotsman2024,
  author = {Klotsman, Michael and Anderson, Wayne H and Wyatt, Danielle and Lewis, Tom and Theus, Natalie and Santoro, Domenico},
  title = {Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate ( OKV ‐1001): A pilot open‐label, single‐arm multicentric clinical trial},
  journal = {Veterinary Dermatology},
  year = {2024},
  doi = {10.1111/vde.13283}
}
Kostenlos starten →